ANI Pharma (ANIP) Tops Q4 EPS by 8c, Revenues Beat; Offers FY19 EPS/Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
ANI Pharmaceuticals Reports Record Full Year and Fourth Quarter 2018 Results and Provides 2019 Guidance
February 27, 2019 8:30 AM ESTBAUDETTE, Minn., Feb. 27, 2019 /PRNewswire/ --
For the full year ended December 31, 2018:
Record net revenues of $201.6 million, an increase of 14% versus 2017 GAAP net income of $15.5 million and diluted GAAP earnings per share of $1.30 Adjusted non-GAAP EBITDA of $84.4 million Adjusted non-GAAP diluted earnings per share of $5.07For the fourth quarter 2018:
Record net revenues of $57.1 million, an increase of 21% versus 2017 GAAP net income of $5.4 million and diluted GAAP earnings per share of $0.46 Adjusted non-GAAP EBITDA of $22.2 million... More